EAM
PALI icon

Exome Asset Management’s Palisade Bio PALI Stock Holding History

Exome Asset Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-600,000
Closed -$1.05M – 65
2026
Q1 		$1.05M Sell
600,000
-158,203
-21% -$288K 0.54% 50
2025
Q4 		$1.78M Buy
+758,203
New +$1.46M 0.85% 44

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Exome Asset Management's PALI Position: Q2 2026 in Review

Exome Asset Management sold out of Palisade Bio (PALI) in Q2 2026, closing a stake of 600,000 shares — an estimated $1.05M sold.

Exome Asset Management first reported a position in PALI in Q4 2025 and held it in 2 quarters. The position peaked at $1.78M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Exome Asset Management reported no remaining Palisade Bio position as of Q2 2026 after selling out during the quarter.
  • Exome Asset Management sold 600,000 Palisade Bio shares in Q2 2026, an estimated $1.05M.
  • Exome Asset Management first reported a position in Palisade Bio in Q4 2025 and held it in 2 quarters.
  • Exome Asset Management's Palisade Bio position peaked at $1.78M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.